Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
about
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds.Outpatient therapeutic nuclear oncology.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Cancer radioimmunotherapy.Trial Watch: Monoclonal antibodies in cancer therapyPharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsIn vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting.The use of antibodies in the prophylaxis and treatment of infections.Improvement of radioimmunotherapy using pretargeting.Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.Pretargeting: taking an alternate route for localizing radionuclides.Using antibodies to target cancer therapeutics.Pretargeted molecular imaging and radioimmunotherapy.Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.MR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model.Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.Recent advances of bispecific antibodies in solid tumors.The making of bispecific antibodiesAntibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT.
P2860
Q33409137-7D4602BB-F3F0-4F08-86BB-363AA036CC8DQ33414032-0D4DC864-9D4C-4A9C-B09F-3B4172689F38Q34180012-E4C2E5DD-675B-45C3-8BB4-760EEB21B205Q34244990-CC0585A2-A4C4-45E3-B474-ECE36B1263C4Q34550963-D415EB1C-B859-41F4-B86C-72DF793B6AB8Q35070045-D38BC7E2-D0E7-4F44-AFEA-48BE12D2F1E9Q36038408-60A00CBE-65FD-4A4E-B38F-F071A22EC9DEQ36323585-B856D51F-B118-4FFC-81E3-F04140FB9DA9Q36337238-EE04FFE9-DBFD-4FD1-8057-C97FF4C04FA3Q36779708-70D23D1A-7540-4B97-A764-F442C4554E2BQ36941931-370C6C8D-7B93-4746-9FC9-602785A77D5CQ37323292-8B519693-6ABA-4CBA-A87A-2243725C5C5AQ37991245-9105AC8F-985F-4B28-8113-8CE0262E383FQ38014920-A727DD05-72C0-491A-B487-DA54273A3545Q38022016-70C63CBF-E74C-4CF3-9E54-DDFAF4BA4A61Q38095962-88E7D50E-EA1E-4A04-94F8-E0A38DCBDEE4Q38206206-660D81A5-6061-4BA2-A6E5-EFCD062DE300Q39051661-AA486E38-B20D-4D26-B319-862F6E56FC6AQ39144294-E17F2E12-338A-4074-A9B7-826F95BC2A61Q39486574-9FFBD7EF-11F7-4FB3-BB13-DBD511046DDAQ41696278-68A2A954-8B1E-40B5-8604-B020FC9B4491Q42323236-B12DAB9F-7B7D-452C-92BF-69B5771A1D5DQ44384601-5D6ACF72-83F3-4529-A7D6-13C9C8F71BBEQ54257268-9946EE20-C1CA-42A7-9C87-F8DCDD5ED363Q55286801-3FEE404B-AAFE-4C10-B9DF-9D329D1CE0DF
P2860
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@en
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@nl
type
label
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@en
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@nl
prefLabel
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@en
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@nl
P2093
P2860
P1476
Recombinant bispecific monoclo ...... retargeted radioimmunotherapy.
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Edmund A Rossi
Robert M Sharkey
William J McBride
P2860
P304
P356
10.1053/J.SEMNUCLMED.2009.12.002
P577
2010-05-01T00:00:00Z